A risk-based approach to experimental early phase clinical trials during the COVID-19 pandemic

Lancet Oncol. 2020 Jul;21(7):889-891. doi: 10.1016/S1470-2045(20)30339-9.

Authors

Crescens Tiu¹, Rajiv Shinde¹, Christina Yap², Bindumalini Rao Baikady¹, Udai Banerji¹, Anna R Minchom¹, Johann S de Bono¹, Juanita S Lopez³

Affiliations

¹ Phase I Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, UK.
² Institute of Cancer Research's Clinical Trials and Statistics Unit, Sutton, UK.
³ Phase I Drug Development Unit, The Royal Marsden Hospital and The Institute of Cancer Research, Sutton, UK. Electronic address: Juanita.Lopez@icr.ac.uk.

No abstract available

MeSH terms

Antiviral Agents / therapeutic use
Betacoronavirus
COVID-19
Clinical Trials, Phase I as Topic* / statistics & numerical data
Coronavirus Infections / epidemiology*
Coronavirus Infections / prevention & control
Data Management
Humans
Neoplasms / drug therapy*
Pandemics / prevention & control
Pneumonia, Viral / epidemiology*
Pneumonia, Viral / prevention & control
Risk Assessment
SARS-CoV-2
United Kingdom / epidemiology

Substances

Antiviral Agents

Grants and funding